Company intelligence / Profile preview
Eli Radiopharma
Suzhou, Chinaeliradiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Eli Radiopharma is an emerging biotechnology company focused on the development of next-generation radiopharmaceuticals for the diagnosis and treatment of cancer. The company leverages a proprietary discovery platform to design targeted ligands that deliver radioactive isotopes directly to tumor cells while minimizing off-target effects. Their primary focus is on targeting Fibroblast Activation Protein (FAP), a protein highly expressed in the stroma of various solid tumors. Eli Radiopharma aims to advance its lead candidates into clinical trials to address significant unmet needs in oncology.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Eli Radiopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eli Radiopharma.